🟢 Novo Nordisk A/S is trading 4.4% up today on positive obesity drug updates and UK Wegovy approval

Novo Nordisk A/S is trading 4.4% up now at $292.55, extending a rebound after earlier mid-June weakness as investors react to positive clinical and regulatory developments.

• The move follows the UK approval of the daily Wegovy weight-loss pill and strong trial data for CagriSema, both of which are central to the company's obesity and diabetes franchise.
• The positive updates continue to support long-term growth expectations for the pharmaceutical giant, helping the stock outperform despite broader market volatility.